Chronic Myelogenous Leukemia Treatment Market, Global Outlook and Forecast 2022-2028

March 2022 | 66 pages | ID: C210760B93B0EN
Market Monitor Global

Abstracts

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. It's a type of cancer that starts in certain blood-forming cells of the bone marrow.

This report contains market size and forecasts of Chronic Myelogenous Leukemia Treatment in Global, including the following market information:

Global Chronic Myelogenous Leukemia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chronic Myelogenous Leukemia Treatment market was valued at 4627.9 million in 2021 and is projected to reach US$ 5942.6 million by 2028, at a CAGR of 3.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Disease Specific Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Myelogenous Leukemia Treatment include Bristol-Myers Squibb, Novartis, Pfizer, Teva Pharmaceuticals, Roche, Incyte and Bio-Path Holdings, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Myelogenous Leukemia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Myelogenous Leukemia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Myelogenous Leukemia Treatment Market Segment Percentages, by Type, 2021 (%)

• Disease Specific Treatment
• Symptomatic Treatment

Global Chronic Myelogenous Leukemia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chronic Myelogenous Leukemia Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies

Global Chronic Myelogenous Leukemia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Myelogenous Leukemia Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Myelogenous Leukemia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chronic Myelogenous Leukemia Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bristol-Myers Squibb
• Novartis
• Pfizer
• Teva Pharmaceuticals
• Roche
• Incyte
• Bio-Path Holdings

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Chronic Myelogenous Leukemia Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Chronic Myelogenous Leukemia Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CHRONIC MYELOGENOUS LEUKEMIA TREATMENT OVERALL MARKET SIZE

2.1 Global Chronic Myelogenous Leukemia Treatment Market Size: 2021 VS 2028
2.2 Global Chronic Myelogenous Leukemia Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Chronic Myelogenous Leukemia Treatment Players in Global Market
3.2 Top Global Chronic Myelogenous Leukemia Treatment Companies Ranked by Revenue
3.3 Global Chronic Myelogenous Leukemia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Chronic Myelogenous Leukemia Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chronic Myelogenous Leukemia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Myelogenous Leukemia Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Chronic Myelogenous Leukemia Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Chronic Myelogenous Leukemia Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Chronic Myelogenous Leukemia Treatment Market Size Markets, 2021 & 2028
  4.1.2 Disease Specific Treatment
  4.1.3 Symptomatic Treatment
4.2 By Type - Global Chronic Myelogenous Leukemia Treatment Revenue & Forecasts
  4.2.1 By Type - Global Chronic Myelogenous Leukemia Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Chronic Myelogenous Leukemia Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Chronic Myelogenous Leukemia Treatment Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacies
  5.1.3 Specialty Pharmacies
  5.1.4 Retail Pharmacies
5.2 By Application - Global Chronic Myelogenous Leukemia Treatment Revenue & Forecasts
  5.2.1 By Application - Global Chronic Myelogenous Leukemia Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Chronic Myelogenous Leukemia Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Chronic Myelogenous Leukemia Treatment Market Size, 2021 & 2028
6.2 By Region - Global Chronic Myelogenous Leukemia Treatment Revenue & Forecasts
  6.2.1 By Region - Global Chronic Myelogenous Leukemia Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Chronic Myelogenous Leukemia Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Chronic Myelogenous Leukemia Treatment Revenue, 2017-2028
  6.3.2 US Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.3.3 Canada Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.3.4 Mexico Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Chronic Myelogenous Leukemia Treatment Revenue, 2017-2028
  6.4.2 Germany Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.4.3 France Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.4.4 U.K. Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.4.5 Italy Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.4.6 Russia Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.4.8 Benelux Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Chronic Myelogenous Leukemia Treatment Revenue, 2017-2028
  6.5.2 China Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.5.3 Japan Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.5.4 South Korea Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.5.6 India Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Chronic Myelogenous Leukemia Treatment Revenue, 2017-2028
  6.6.2 Brazil Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.6.3 Argentina Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Chronic Myelogenous Leukemia Treatment Revenue, 2017-2028
  6.7.2 Turkey Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.7.3 Israel Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028
  6.7.5 UAE Chronic Myelogenous Leukemia Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bristol-Myers Squibb
  7.1.1 Bristol-Myers Squibb Corporate Summary
  7.1.2 Bristol-Myers Squibb Business Overview
  7.1.3 Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.1.4 Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.1.5 Bristol-Myers Squibb Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.2.4 Novartis Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.2.5 Novartis Key News
7.3 Pfizer
  7.3.1 Pfizer Corporate Summary
  7.3.2 Pfizer Business Overview
  7.3.3 Pfizer Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.3.4 Pfizer Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.3.5 Pfizer Key News
7.4 Teva Pharmaceuticals
  7.4.1 Teva Pharmaceuticals Corporate Summary
  7.4.2 Teva Pharmaceuticals Business Overview
  7.4.3 Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.4.4 Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.4.5 Teva Pharmaceuticals Key News
7.5 Roche
  7.5.1 Roche Corporate Summary
  7.5.2 Roche Business Overview
  7.5.3 Roche Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.5.4 Roche Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.5.5 Roche Key News
7.6 Incyte
  7.6.1 Incyte Corporate Summary
  7.6.2 Incyte Business Overview
  7.6.3 Incyte Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.6.4 Incyte Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.6.5 Incyte Key News
7.7 Bio-Path Holdings
  7.7.1 Bio-Path Holdings Corporate Summary
  7.7.2 Bio-Path Holdings Business Overview
  7.7.3 Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Major Product Offerings
  7.7.4 Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue in Global Market (2017-2022)
  7.7.5 Bio-Path Holdings Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Chronic Myelogenous Leukemia Treatment Market Opportunities & Trends in Global Market
Table 2. Chronic Myelogenous Leukemia Treatment Market Drivers in Global Market
Table 3. Chronic Myelogenous Leukemia Treatment Market Restraints in Global Market
Table 4. Key Players of Chronic Myelogenous Leukemia Treatment in Global Market
Table 5. Top Chronic Myelogenous Leukemia Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chronic Myelogenous Leukemia Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chronic Myelogenous Leukemia Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chronic Myelogenous Leukemia Treatment Product Type
Table 9. List of Global Tier 1 Chronic Myelogenous Leukemia Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Myelogenous Leukemia Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chronic Myelogenous Leukemia Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chronic Myelogenous Leukemia Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chronic Myelogenous Leukemia Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chronic Myelogenous Leukemia Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Bristol-Myers Squibb Corporate Summary
Table 31. Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Product Offerings
Table 32. Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Chronic Myelogenous Leukemia Treatment Product Offerings
Table 35. Novartis Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Chronic Myelogenous Leukemia Treatment Product Offerings
Table 38. Pfizer Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Teva Pharmaceuticals Corporate Summary
Table 40. Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Product Offerings
Table 41. Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Roche Corporate Summary
Table 43. Roche Chronic Myelogenous Leukemia Treatment Product Offerings
Table 44. Roche Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Incyte Corporate Summary
Table 46. Incyte Chronic Myelogenous Leukemia Treatment Product Offerings
Table 47. Incyte Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Bio-Path Holdings Corporate Summary
Table 49. Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Product Offerings
Table 50. Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Chronic Myelogenous Leukemia Treatment Segment by Type in 2021
Figure 2. Chronic Myelogenous Leukemia Treatment Segment by Application in 2021
Figure 3. Global Chronic Myelogenous Leukemia Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chronic Myelogenous Leukemia Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chronic Myelogenous Leukemia Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Myelogenous Leukemia Treatment Revenue in 2021
Figure 8. By Type - Global Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 12. US Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 24. China Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chronic Myelogenous Leukemia Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chronic Myelogenous Leukemia Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Bristol-Myers Squibb Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Teva Pharmaceuticals Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Roche Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Incyte Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Bio-Path Holdings Chronic Myelogenous Leukemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)